Antiretroviral treatment during pregnancy

AIDS

Volumn 22, Issue 17, 2008, Pages 2323-2330

  Keiser, Olivia ^a   Gayet Ageron, Angèle ^b   Rudin, Christoph ^c   Brinkhof, Martin W G ^a   Gremlich, Erika ^d   Wunder, Dorothea ^e   Drack, Gero ^f   Hirschel, Bernard ^b   Martinez De Tejada, Begoña ^b   Aebi, C ^f   Battegay, M ^f   Bernasconi, E ^f   Boni J ^f   Brazzola, P ^f   Bucher, H C ^f   Burgisser Ph ^f   Calmy, A ^f   Cattacin, S ^f   Cavassini, M ^f   Cheseaux, J J ^f   Drack, G ^f   Dubs, R ^f   Egger, M ^f   Elzi, L ^f   Fischer, M ^f   Flepp, M ^f   Fontana, A ^f   Francioli, P ^g   Furrer, H J ^f   Fux, C ^f   Gayet Ageron, A ^f   Gerber, S ^f   Gorgievski, M ^f   Grawe, C ^f   Gunthard H ^f   Gyr, Th ^f   Hirsch, H ^f   Hirschel, B ^f   Hosli I ^f   Husler M ^f   Kaiser, L ^f   Kahlert, Ch ^f   Karrer, U ^f   Kind, C ^f   Klimkait, Th ^f   Ledergerber, B ^f   Martinerti, G ^f   Martinez, B ^f   Muller N ^f   Nadal, D ^f   Opravil, M ^f   Paccaud, F ^f   Pantaleo, G ^f   Rauch, A ^f   Regenass, S ^f   Rickenbach, M ^f   Rudin, C ^c   Schmid, P ^f   Schultze, D ^f   Schupbach J ^f   Speck, R ^f   Taffe P ^f   Telenti, A ^f   Trkola, A ^f   Vernazza, P ^f   Weber, R ^f   Wunder, D ^f   Wyler, C A ^f   Yerly, S ^f   more..

^a UNIVERSITY OF BERN   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f Department of Obstetrics and Gynecology ^*

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Antiretroviral therapy; Pregnancy; Treatment changes; Virologic failure; Women

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; NEVIRAPINE; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL TOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MATERNAL AGE; MONOTHERAPY; NEUROTOXICITY; PREGNANCY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SWITZERLAND; TREATMENT FAILURE; VIRUS LOAD;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; GESTATIONAL AGE; HIV INFECTIONS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS; RNA, VIRAL; VIRAL LOAD; YOUNG ADULT;

EID: 56549107940     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283189bf1     Document Type: Article

References (40)

1. Egger] M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
2. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-1730.
3. Pregnancy and HIV: CCT recommendations for the prevention of mother-to-child transmission of HIV. Recommendations during pregnancy to prevent infant infection. Clinical and Therapeutic commission for HIV/AIDS [in Italian]. Bulletin OFSP 2005;53:1008.
4. Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Public Health Service Task Force. 2 November, 2007. http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf. [Accessed 9 December, 2007].
5. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
6. Thorne C, Newell ML. Prevention of mother-to-child transmission of HIV infection. Curr Opin Infect Dis 2004; 17:247-252.
7. Newell ML, Thorne C. Antiretroviral therapy and mother-to-child transmission of HIV-1. Expert Rev Anti Infect Ther 2004; 2:717-732.
8. Mirochnick M. Antiretroviral pharmacology in pregnant women and their newborns. Ann NY Acad Scei 2000; 918:287-297.
9. Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998; 178:368-374.
10. Rakhmanina NY, van den Anker JN, Soldin SJ. Safety and pharmacokinetics of antiretroviral therapy during pregnancy. Ther Drug Monit 2004; 26:110-115.
11. O'Sullivan MJ, Boyer PJ, Scott GB, Parks WP, Weller S, Blum MR, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. Am J Obstet Gynecol 1993; 168:1510-1516.
12. van Heeswijk RP, Khaliq Y, Gallicano KD, Bourbeau M, Seguin I, Phillips EJ, Cameron DW. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin Pharmacol Ther 2004; 76:588-597.
13. Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet 1997; 33:328-343.
14. Hirt D, Treluyer JM, Jullien V, Firtion G, Chappuy H, Rey E, et al. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women. Antimicrob Agents Chemother 2006; 50:2079-2086.
15. Watts DH, Covington DL, Beckerman K, Garcia P, Scheuerle A, Dominguez K, et al. Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy. Am J Obstet Gynecol 2004; 191:985-992.
16. Natarajan U, Pym A, McDonald C, Velisetty P, Edwards SG, Hay P, et al. Safety of nevirapine in pregnancy. HIV Med 2007; 8:64-69.
17. Lyons F, Hopkins S, Kelleher B, McGeary A, Sheehan G, Geoghegan J, et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med 2006; 7:255-260.
18. Marti C, Pena JM, Bates I, Madero R, de Jose I, Pallardo LF, et al. Obstetric and perinatal complications in HIV-infected women. Analysis of a cohort of 167 pregnancies between 1997 and 2003. Acta Obstet Gynecol Scand 2007; 86:409-415.
19. Dube MP, Sattler FR. Metabolic complications of antiretroviral therapies. AIDS Clin Care 1998; 10:41-44.
20. Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Infect 2002; 78:58-59.
21. Ledergerber B, von Overbeck J, Egger M, Luthy R. The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Praventivmed 1994; 39:387-394.
22. Sudre P, Rickenbach M, Taffe P, Janin P, Volkart AC, Francioli P. Clinical epidemiology and research on HIV infection in Switzerland: the Swiss HIV Cohort Study. Schweiz Med Wochenschr 2000; 130:1493-1500.
23. Battegay M, Fluckiger U, Hirschel B, Furrer H. Late presentation of HIV-infected individuals. Antivir Ther 2007; 12:841-851.
24. Mofenson LM, Lambert JS, Stiehm ER, Bethel J, Meyer WA 3rd, Whitehouse J, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999; 341:385-393.
25. Patel D, Cortina-Borja M, Thorne C, Newell ML. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis 2007; 44:1647-1656.
26. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173-1180.
27. Wade NA, Birkhead GS, Warren BL, Charbonneau TT, French PT, Wang L, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998; 339:1409-1414.
28. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354:1084-1089.
29. Culnane M, Fowler M, Lee SS, McSherry G, Brady M, O'Donnell K, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA 1999; 281:151-157.
30. Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Stare TJ, Bricker JT, et al. Absence of cardiac toxicity of zidovudine in infants. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med 2000; 343:759-766.
31. Villani P, Floridia M, Pirillo MF, Cusato M, Tamburrini E, Cavaliere AF, et al. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. Br J Clin Pharmacol 2006; 62:309-315.
32. Hayashi S, Beckerman K, Homma M, Kosel BW, Aweeka FT. Pharmacokinetics of indinavir in HIV-positive pregnant women. AIDS 2000; 14:1061-1062.
33. Bardeguez AD, Lindsey JC, Shannon M, Tuomala RE, Cohn SE, Smith E, et al. Adherence to antiretrovirale among US women during and after pregnancy. J Acquir Immune Defic Syndr 2008; 48:408-417.
34. Mellins CA, Chu C, Malee K, Allison S, Smith R, Harris L, et al. Adherence to antiretroviral treatment among pregnant and postpartum HIV-infected women. AIDS Care 2008; 20:1-11.
35. Australian HIV observational database. Rates of combination antiretroviral treatment change in Australia, 1997-2000. HIV Med 2002;3:28-36.
36. Gebhardt M, Rickenbach M, Egger M. Impact of antiretroviral combination therapies on AIDS surveillance reports in Switzerland. Swiss HIV Cohort Study. AIDS 1998; 12:1195-1201.
37. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-868.
38. Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. JAMA 2000; 283:205-211.
39. Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis 2005; 41:1326-1332.
40. Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, Collier AC, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 2001; 286:171-179.